|
|
 |
|
|
|
|
|
|
Case histories
A blockbuster built on complementary strengths.
Plavix®/Iscover® (clopidogrel bisulfate tablets)
Both Sanofi-Synthelabo and Bristol-Myers Squibb believed that Plavix®/Iscover® (clopidogrel bisulfate tablets) could help manage arterial thrombosis in millions of patients. Each company also had individual goals -- Sanofi-Synthelabo to build a greater presence in the U.S., and Bristol-Myers Squibb to strengthen its cardiovascular market position.
The two companies pooled their strengths to maximize clopidogrel's therapeutic potential, with technical knowledge and a powerful European regulatory and sales organization from Sanofi-Synthelabo and historic strengths in cardiovascular products, sales and marketing, and clinical development from Bristol-Myers Squibb.
Two major studies demonstrated significant value, both competing with and augmenting the standard therapy of aspirin. The product grew to more than $2 billion in five years, while both partners moved towards their individual goals. Sanofi-Synthelabo has a greater U.S. presence, and is listed on the New York Stock Exchange. And we have strengthened our position as a leader in cardiovascular medicine, worldwide.
|
[Top Page] [Search]
[Index] [Contact] [Home]
Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.
© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy. |
|
|
